Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
Subscribe To Our Newsletter & Stay Updated
